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Abstract
Background: There is evidence that homocysteine con-
tributes to various neurodegenerative disorders. Objec-
tive: To assess the values of homocysteine in patients
with Creutzfeldt-Jakob disease (CJD) in both cerebrospi-
nal fluid (CSF) and plasma. Methods: Study design: Case
control study. Total homocysteine was quantified in CSF
and plasma samples of CJD patients (n = 13) and healthy
controls (n = 13). Results: Mean values in healthy con-
trols: 0.15 Ìmol/l B 0.07 (CSF) and 9.10 Ìmol/l B 2.99
(plasma); mean values in CJD patients: 0.13 Ìmol/l B
0.03 (CSF) and 9.22 Ìmol/l B 1.81 (plasma). No signifi-
cant differences between CJD patients and controls were
observed (Mann-Whitney U, p 1 0.05). Conclusions: The
results indicate that the CSF and plasma of CJD patients
showed no higher endogenous levels of homocysteine
as compared to normal healthy controls. These findings
provide no evidence for an additional role of homocys-
teine in the pathogenetic mechanisms underlying CJD
neurodegeneration.
Copyright © 2005 S. Karger AG, Basel
Introduction
Elevated plasma homocysteine concentrations are
linked to neuropsychiatric disorders such as alcoholism
and alcohol-related brain atrophy [3], Alzheimer‘s disease
(AD), and cognitive impairment [8]. Furthermore, in-
creased plasma homocysteine levels are an independent
risk factor for the development of AD [8]. Homocysteine
is a neurotoxic excitatory amino acid, which plays a role
in a shared biochemical cascade involving overstimula-
tion of N-methyl-D-aspartate (NMDA) receptors, oxida-
tive stress, activation of caspases, DNA damage, and
mitochondrial dysfunction. These mechanisms are be-
lieved to be important in the pathogenesis of neurotoxici-
ty and excitotoxicity [3, 6].
Prion diseases or spongiform encephalopathies are a
group of fatal neurodegenerative disorders including
Creutzfeldt-Jakob disease (CJD). Since the chemical com-
position of human cerebrospinal fluid (CSF) is considered
to reflect brain metabolism, we investigated homocys-
teine levels in the CSF of CJD patients and healthy con-
trols. Additionally, plasma samples were examined for
total homocysteine levels. It was the aim of the present
pilot study to assess the possible involvement of homocys-
teine in the pathogenesis of CJD.
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Methods
The present case control study was approved by the local Ethics
Committee. Diagnosis of CJD and laboratory investigations were
performed as previously described [1, 7, 10]. 13 CJD patients were
examined clinically by a member of the German CJD Surveillance
Study Group and each patient underwent a detailed neurologic
examination. The mean age of CJD patients was 65.8 years (range
53.8–83.5 years). All patients of this group have succumbed to their
disease, and the diagnosis CJD was confirmed neuropathologically
using immunohistochemistry for the prion protein in all cases. 14-3-3
protein was detected according to various methods [7, 10, 11] in all
13 CJD patients. The controls consisted of 13 healthy subjects with
normal cognition and without a diagnosis of any psychiatric or neu-
rologic disease. After complete description of the study to the sub-
jects, written informed consent was obtained. Controls were matched
to cases by age and gender.
Screening for non-genetic factors possibly associated with ele-
vated homocysteine levels such as lifestyle (alcohol abuse, nutritional
status, medication), endocrinological conditions and other diseases
(i.e. diabetes mellitus, cardiovascular diseases), laboratory methods
and measurements (vitamins B12, B6 and folate) were performed on
the basis of a previous study [2]. All patients and controls were classi-
fied as normally nourished (data not shown). Under these conditions,
a plasma homocysteine reference interval of 4.9–11.7 Ìmol/l was
defined as normal according to Ubbink et al. [9]. Normal ranges for
CSF homocysteine are not known.
Total homocysteine in plasma and cerebrospinal fluid (CSF) was
measured by an enzyme-linked immunosorbent assay (Axis® Homo-
cysteine EIA, Germany/Norway, IBL-No. AX 513 01). Statistical
analysis: The significance of differences between groups was evaluat-
ed by the non-parametric Mann-Whitney U test. Results are present-
ed as the central tendency (mean) B SD. p ! 0.05 (two-tailed) was
considered to indicate statistical significance.
Results
As shown in figure 1, CSF as well as plasma homocys-
teine levels did not differ significantly between CJD
patients (n = 13) and controls (n = 13). Central tendencies
(CT or ‘mean’ B SD in Ìmol/l) in controls: 0.15 B 0.07
(CSF) and 9.10 B 2.99 (plasma); CT values in CJD
patients: 0.13 B 0.03 (CSF) and 9.22 B 1.81 (plasma).
Thus, no significant differences between CJD patients
and controls in respect to homocysteine concentrations in
samples of CSF (Z = –0.46, p = 0.65) and plasma (Z =
–0.33, p = 0.76) were found. Furthermore, in both groups
homocysteine concentrations were within the reference
interval (4.9–11.7 Ìmol/l).
Fig. 1. Cerebrospinal fluid and plasma homocysteine levels in
patients with CJD and controls.
Discussion
To our knowledge, this is the first study evaluating
homocysteine levels in patients suffering from (sporadic)
CJD. However, we did not detect any significant differ-
ences of homocysteine levels in CSF or plasma. A number
of reviews detail acute or chronic pathophysiology in
which free radicals and homocysteine express their toxici-
ty in neurodegenerative disorders [5]. Taking into account
that there is no evidence of oxidative stress in CJD
patients [1] the results of the present study are in line with
these previous observations. However, determining ho-
mocysteine levels in an earlier stage of CJD patients
might deliver other results. Despite the identification of
hyperhomocysteinemia as an independent risk factor for
neurodegenerative disorders such as AD [8], little is
known about the presence of homocysteine in the CSF.
However, similar results were found in a recent study of
18 healthy adults with CSF homocysteine concentrations
between 0.015 and 0.140 Ìmol/l [4].
Furthermore, it must be taken into account that an
intracellular accumulation of homocysteine leads to hy-
perhomocysteinemia. Thus, the neurotoxicity of homo-
cysteine is not only caused by an elevated extracellular
homocysteine concentration, but especially by the toxic
effects that can be triggered by the intracellular hyperho-
mocysteinemia and can affect the intracellular compart-
ments [3].
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Since we could not disclose an intracellular accumula-
tion of homocysteine, further studies are needed which
should be directed to CJD brain tissue. However, at this
moment we conclude that homocysteine possibly does not
play a pathophysiological role in CJD and may not serve
as a biological marker of CJD but may be useful in the
differential diagnosis of other neurodegenerative disor-
ders, in particular AD.
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